Yes, study came out in 2022, but this is why conferences are so important so we can have interdisciplinary conversations and discuss complex data as a group. Raw tezt here is anyone wants: www.acpjournals.org/doi/full/10....

The trial was repeated in 3 other countries and... yes. The effect decreased. It decreased as more health workers had more antibodies and greater immunity as time went on. By the 3rd wave, effect was lost. But for the first 2 waves N95 were crucial for saving lives!

In Canada surgeons actually did a randomized trial, of their surgeons wearing normal PPE or the N95 mask. They ignored anyone who had COVID before, only looked at first infections, N95 masks clearly made a major difference preventing infection in the first 2 waves of the pandemic.

I've an MSc student doing this now... Or rather testing the culture mediums each time to see how pure they are. Am curious what the results show

Option 1) 99% standard solvent, 1% deuterated.
Stretch those supplies. out make it last!
Option 2) 100% standard solvent, glass insert with deuterated for lock - reusable.

Really helps with solvent shimming and baseline.
Both options still give massive solvent peak but suppression is very good now

I know it really isn't the answer you're looking for but I've found 2 options for my lab to run standard routines on non publication critical work - to a certain extent both rely on solvent suppression (NOESY has come a long way).
It means any solvent - sample overlaps are... yeah. not good

All absolutely necessary though. And we were developing medical diagnostics - devices to test for disease. The ethical approval hoops we jumped through to help treat people and make them better. There's a reason you only let clinical professionals handle this - wouldn't dream of doing ourselves

Polymer nanotechnology functional contact lens I produced in labs as part of a postdoctoral project went to pre-clinical, animal efficacy and safety trials about 10 years ago. The paperwork producing SOPs for production, setting sterility batch testing procedures, packaging and shipping... wow.

Just arrived in the hotel ready for the morning start. Am an academic biomaterials scientist very keen to explore our technologies in infection management.

If I see you (or you see me, Tom Swift, please do say Hi as this is my first time)

A fortnight ago we got another rejection that simply said 'we are solely focused on technologies in an advanced state'...

We have 2 granted international patent families! We have £20k funding to launch a spin out company. How much more advanced do you need?